A prospective multicenter study of intermittent chemotherapy with docetaxel and prednisolone for castration-resistant prostate cancer-Reference-Cited by-同舟云学术

A prospective multicenter study of intermittent chemotherapy with docetaxel and prednisolone for castration-resistant prostate cancer

Published:2016-06-01 Issue:6 Volume:46 Page:547-553
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Narita Shintaro¹,Koie Takuya²,Yamada Shigeyuki³,Orikasa Kazuhiko⁴,Matsuo Shigeki⁵,Aoki Hiroshi⁶,Ishidoya Shigeto⁶,Hoshi Senji⁷,Tsuchiya Norihiko¹,Ohyama Chikara²,Arai Yoichi³,Habuchi Tomonori¹

Affiliation:

1. Department of Urology, Akita University School of Medicine, Akita

2. Department of Urology, Hirosaki University School of Medicine, Hirosaki

3. Department of Urology, Tohoku University School of Medicine, Tohoku

4. Department of Urology, Kesen-numa City Hospital, Kesen-numa

5. Department of Urology, Akita City Hospital, Akita

6. Department of Urology, Sendai City Hospital, Sendai

7. Department of Urology, Yamagata Prefectural Central Hospital, Michinoku Japan Urological Cancer Study Group (MJUCSG), Yamagata, Japan

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/46/6/547/26649956/hyw021.pdf

Reference24 articles.

1. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014

2. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

4. Cytotoxic chemotherapy in the contemporary management of metastatic prostate cancer;Sonpavde;BJU Int,2015

5. Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer;Klotz;Curr Urol Rep,2013

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing the future: how mathematical models inform treatment schedules for cancer;Trends in Cancer;2022-06

2. GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol);Therapeutic Advances in Medical Oncology;2022-01

3. Maintenance Long-Term Multiple Cycles Treatment with Docetaxel in Metastatic Castration-Resistant Prostate Cancer: A Report of Three Cases;OncoTargets and Therapy;2021-04

4. Prognostic value of ECOG performance status and Gleason score in the survival of castration-resistant prostate cancer: a systematic review;Asian Journal of Andrology;2021

5. Establishing patient-tailored variability-based paradigms for anti-cancer therapy: Using the inherent trajectories which underlie cancer for overcoming drug resistance;Cancer Treatment and Research Communications;2020